

A M E N D M E N T

Please amend the claims as follows:

C18p2  
5. (Amended) A method according to any of claims 1, 2 or 3, wherein said xenogeneic DNA is human DNA[, and/or wherein said xenogeneic DNA is immunoglobulin DNA in substantially intact form].

sub 3  
C2  
6. (Amended) Embryonic stem cells comprising a genome modified according to the method of claims 1, 4, [or] 5 or 12.

7. (Amended) A modified animal produced according to the method of claims 2, 3, 4, [or] 5 or 12.

C3 sub 4  
9. (Amended) The stem cells of claim 8 which are [murine] of a mouse.

R E M A R K S

Pending claims 1-12 have been finally rejected. Claims 5-7 and 9 have been amended to resubmit the same amendatory language as per Applicants' previous submission. Careful consideration has been given to the grounds of rejection, and the following discussion is offered in response. Reconsideration is requested.

Applicants acknowledge that the Examiner's Action has made rejections based on double patenting, and reiterate their intention to respond substantively once allowable subject matter